TRPV4 is a polymodal cation channel gain-of-function (GOF) allele which causes skeletal dysplasia in humans. To better understand its gating, we screened for additional GOF alleles based on their ability to block yeast proliferation. Repeatedly, only a limited number of such growth-blocking mutations were isolated. Expressed in oocytes, wild-type channels can be strongly activated by either hypotonicity or exposure to the potent agonist 4␣PDD, although the GOF channels behaved as if they were fully prestimulated as well as lacking a previously uncharacterized voltage-dependent inactivation. Five of six mutations occurred at or near the inner ends of the predicted core helices, giving further direct evidence that this region indeed forms the main intracellular gate in TRP channels. Surprisingly, both wild-type channels as well as these GOF channels maintain strong steady-state outward rectification that is not due to a Ca 2؉ block, as has been proposed elsewhere. We conclude that TRPV4 contains an additional voltage-dependent gating mechanism in series with the main intracellular gate.
Transient receptor potential (TRP)2 channels are a functionally and evolutionarily diverse group of cation-selective channels characterized by polymodal gating to chemical, thermal, mechanical as well as other stimuli (1). Predicted transmembrane topology and cryomicroscopic images (2) indicate that TRPs are structurally similar to other cationic channels such as the voltage-gated K ϩ channels (3). Each of the four subunits (4) is modeled to have six transmembrane helices (S1-S6), where S1-S4 forms the peripheral domain and the four S5-S6 domains converge to form the core, with the S6 lining the ion pathway. An ion filter is found in the pathway near the outer half (5). Structural homology to K ϩ channels (3) indicates (6, 7) and direct mutational analysis supports (8) that the cytoplasmic ends of the four S6 conditionally converge to occlude the pathway, creating an intracellular gate.TRPV4, of the vanilloid class of TRP channels, originally drew attention and was isolated based on its ability to respond to hypotonic stress (9, 10). It was subsequently found to also be activated by heat (11), the arachidonic acid (AA) metabolite 5Ј,6Ј-epoxyeicosatrienoic acid (5Ј,6Ј-EET) (12) as well as other compounds (13,14), but the most potent activator was found to be an exogenous agonist, 4␣-phorbol 12,13-didecanoate (4␣PDD) (15). 4␣PDD and hypotonicity were found to activate TRPV4 through distinct pathways (16). In cultured kidney cells, hypotonicity is thought to activate TRPV4 through the production of 5Ј,6Ј-EET, possibly by activating phospholipase A2 (16). There must be other mechanisms by which TRPV4 is activated by hypotonicity, since it maintains robust hypotonic activation when expressed in yeast, which is incapable of synthesizing polyunsaturated fatty acids such as AA and its metabolites (17). TRPV4 is expressed in a broad range of tissue types that have varying physiological relevance (18). TRPV4Ϫ/Ϫ knock-out mice are compromised...